$TDOC

Teladoc (NYSE:TDOC) exceeds Q3 2026 expectations, stock jumps 11.5%

Teladoc (TDOC) reported Q3 2026 revenue of $605.1M, beating estimates by 2.8%, with EPS of -$0.15, a 30% beat. Adjusted EBITDA was $79.36M, a 16.6% beat. Q4 revenue guidance of $592M is slightly below estimates, while full-year EPS and EBITDA guidance beat expectations. Operating margin improved to -4.6% from -8.3% YoY, and free cash flow margin rose to 12.5% from 10.5% QoQ.

Original reporting
Published Oct 28, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Teladoc (NYSE:TDOC) exceeds Q3 2026 expectations, stock jumps 11.5% — source image
Decision brief

The 30-second read

$TDOCBullishHigh
01

Why it matters

The earnings beat and positive guidance lifted the stock 11.5% in after‑hours trading, suggesting strong short‑term buying interest.

02

Market read

First‑report earnings beat for a mid‑cap telehealth firm, driving notable price movement and sector momentum.

03

What to watch

Potential headwinds from payer reimbursement pressures and competitive pricing.

Relevance 9/10Novelty 9/10Timing: after-hours release

Background

Teladoc reported Q3 2026 results with revenue of $605.1M versus $588.4M consensus and GAAP EPS of -$0.15 versus -$0.21 consensus.

Company-level read

Ticker impact

$TDOCBullishHigh confidence
Context

Q3 2026 results beat revenue and EPS estimates, prompting an 11.5% stock jump.

Expected impact

likely continued upside as market prices in the earnings beat and raised guidance.

Evidence & confidence

Both top‑line and EPS exceeded consensus, and guidance for Q4 and FY remains above estimates, supporting further buying.

Market effects

Telehealth sector may see broader rally on strong earnings from a leading player.

U.S. market sentiment boosted by a mid‑cap tech earnings beat.

Highlights growing demand for virtual care, potentially influencing global health‑tech investors.

Counterpoint

If guidance falls short of longer‑term growth expectations, the rally could be short‑lived.

Key entities

  • Teladoc Health, Inc.

    Provider of virtual healthcare services.

Related articles

$TDOCHighAI 8/10

Teladoc shares surge 9% on narrower-than-feared loss, raised outlook

Teladoc Health (TDOC) shares rose 9% after Q3 results beat expectations with a loss of -$0.15 per share vs. -$0.22 estimate, and revenue of $605.1M vs. $588.44M estimate. The company raised its full-year outlook, projecting a loss of -$0.75 to -$0.95 per share and revenue of $2.4B to $2.44B. Adjusted EBITDA increased 14% YoY to $79.4M, with the Integrated Care segment showing growth while BetterHelp declined 13% YoY.

$GOOGLHighAI 8/10

After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC

Alphabet (GOOGL) fell 8% after reporting Q3 revenue of $127.6B, missing EPS estimates. Microsoft (MSFT) rose 4% on strong cloud performance. ServiceNow (NOW) dropped 16% after an earnings miss. KLA (KLAC) gained 3% on strong guidance. Chipotle (CMG) rose 2% on revenue beat. Carvana (CVNA) climbed 6% on top-line beat. Teladoc (TDOC) gained 8% on smaller loss and revenue beat.

$TDOCHighAI 8/10

Teladoc: Q3 Earnings Snapshot

Teladoc Inc. (TDOC) reported a Q3 loss of $26.9M, or 15 cents per share, beating analyst expectations of a 23 cents per share loss. Revenue was $605.1M, exceeding forecasts of $585.5M. The company expects Q4 revenue between $569M and $615M, and full-year revenue between $2.4B and $2.44B, with a loss per share between 95 and 75 cents.

$TDOCHighAI 8/10

Teladoc Health Reports Third Quarter 2026 Results

Teladoc Health, Inc. (TDOC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Teladoc Health Reports Third Quarter 2026 Results NEW YORK, October 28, 2026 — Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended September 30, 2026 (“Third Quarter 2026”). Unless otherwis

$TDOCMed

Why is Teladoc stock sliding today?

Teladoc (TDOC) shares fell 2.3% to $5.95 amid leadership transition concerns. The company's CLO resigned, raising governance questions. The stock has declined since Q2 revenue missed expectations and guidance was cut. Analysts have lowered price targets, and institutional selling has increased. The broader market's decline added pressure. TDOC trades near its 52-week low of $4.40.